PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.54%
Revenue growth of 2.54% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
2.13%
Gross profit growth of 2.13% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-4.04%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
8.13%
Operating income growth of 8.13% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
-4.25%
Negative net income growth while Medical - Pharmaceuticals median is 1.89%. Seth Klarman would investigate factors dragging net income down.
-4.26%
Negative EPS growth while Medical - Pharmaceuticals median is 6.67%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-4.26%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 6.52%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.06%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.04%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.82%
10Y CAGR of 38.82% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-10.63%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
34.92%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 6.07%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
189.89%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 23.05% over a decade. Joel Greenblatt might see a standout compounder of earnings.
14.72%
Net income/share CAGR of 14.72% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
61.26%
3Y net income/share CAGR of 61.26% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
132.27%
Equity/share CAGR of 132.27% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
27.36%
5Y equity/share CAGR of 27.36% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
68.35%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.38%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-2.34%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.61%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
3.83%
BV/share growth of 3.83% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-6.07%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
0.53%
SG&A growth of 0.53% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.